Shots:

• NICE has issued a positive FAD which recommends the use of Aspaveli as a treatment option in adults with PNH who are anemic after treatment with a C5 inhibitor in England & Wales
• The recommendation is based on the P-III (PEGASUS) study to evaluate pegcetacoplan vs eculizumab in 80 adults with PNH which showed an improvement in hemoglobin levels & FACIT fatigue scores, reduction in transfusion requirements
• Aspaveli is currently undergoing assessment with the MHRA for marketing authorization in the UK. Sobi & Apellis collaborated to co-develop pegcetacoplan where Sobi gets exclusive ex-US commercialisation rights & Apellis gets US commercialization rights for systemic pegcetacoplan

 Ref: PharmiWeb | Image: Sobi